Fig. 1
Efficacy of L-IFPTA+ vaccine against in hypercholesterolemic C57BL/6 mice, 2 weeks after the last vaccination. a Antibody titers (ODmax/2) against PCSK9 in vaccinated hypercholesterolemic C57BL/6 mice. b Plasma concentration of PCSK9 in the vaccinated and control groups was 116.8 ± 8 ng/mL and 281.5 ± 5.2 ng/mL, respectively. c Direct detection of antibodies bound to plasma PCSK9 in the blood samples from vaccinated and control mice. Elevated OD450 is indicative of vaccine-induced anti-PCSK9 antibodies directly binding to PCSK9. d In vitro PCSK9/LDLR binding assay. Vaccine-induced antibodies inhibited PCSK9/LDLR interaction. The plasma sample of the L-IFPTA+ vaccine group could decrease PCSK9 binding to LDLR by 44.8%, when compared with the plasma sample of the control group. Bars show mean values; error bars show ± SD (n = 3 replicates of the pooled samples of 10 mice per group). Significance compared to control values was analyzed by unpaired two-tailed Student’s t test